GSK tries to lease vacant office space after layoffs; CVS agrees to buy Target's pharmacy biz for $1.9B;

@FiercePharma: G7 vows to combat antibiotics resistance, but animal health groups urge caution. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: ICYMI: Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz label. Report | Follow @CarlyHFierce

> After shedding a fifth of its workforce in Research Triangle Park, NC, GlaxoSmithKline ($GSK) is trying to lease up to 500,000 square feet of its vacant office space for temporary use by state government employees. More

> Startup Intarcia Therapeutics is aiming to disrupt the diabetes care market with a matchstick-size implant. More

> CVS ($CVS) has agreed to buy Target's ($TGT) pharmacy and clinic business for $1.9 billion. Report

> The federal magistrate recommendation that Kirkland & Ellis--lead takeover counsel for Teva ($TEVA) in its quest to buy Mylan ($MYL)--be thrown off the deal could have major law firms quickly redoing their procedures to avoid risking it happening to them. More

> Researchers from Boston Children's Hospital and Merck ($MRK) are looking into the relationship between social media use and sleep issues, and early findings suggest that patients with sleep disorders may be a greater risk of psychosocial issues. More

Medical Device News

@FierceMedDev: ICYMI Friday: Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: India's PM is facing pushback from MSF over access to generic drugs. More from Reuters| Follow @EmilyWFierce

> FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic. Report

> Milestone Pharma raises $17M Series B for Phase II of at-home, drug-device cardiac arrhythmia combo. Story

> Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia. Article

Biotech News

@FierceBiotech: Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Bluebird bio builds its case for gene therapy as first sickle cell patient responds. Article | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> AstraZeneca spells out key failures for gout drug in PhIII. More

> Israel's RedHill soars as its antibiotic comes through in Phase III. Story

> Avalon, GlaxoSmithKline launch 3 new biotechs with $30M commitment. Article

Animal Health News

> AB Science struggles to break out as canine cancer drug flounders. Report

> Rapamycin raises $2.5M to advance lead drug for treating cancer in pets. Item

> G7 vows to combat antibiotics resistance, but animal health groups urge caution. More

> Scientists scrambling to determine if virulent avian flu is airborne. Story

> Lilly quashes rumors of Elanco spinoff as stock soars. Article

Biotech IT News

> EHR-enabled data dive links stomach blockbusters to heart attacks. More

> Allergan slashes laptop use in full-throttle mobile push. Report

> Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact. Story

> The search for exceptional responders in tumor sequencing databases. Item

> J&J teams with Emulate to use organ-on-a-chip technology in R&D programs. Article

Pharma Marketing News

> PatientsLikeMe, FDA partner up to track online drug safety clues. Item

> CoheroHealth's 'smart,' mobile spirometer begins pilots with pharma, payers. News

> Experts urge FDA to step in to quash 'Low-T' awareness efforts. More

> Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market. Story

> Mannkind investors skittish after CEO, CFO update on Afrezza launch. Article

And Finally... A new app from a division of Johnson & Johnson ($JNJ) tells you the exact street where the flu and allergies are lurking in your neighborhood. More

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."